Two-Year Outcomes for Tricuspid Repair With a Transcatheter Edge-to-Edge Valve Repair From the Transatlantic TRILUMINATE Trial
Ralph Stephan von Bardeleben,Philipp Lurz,Paul Sorajja,Tobias Ruf,Jörg Hausleiter,Marta Sitges,Jaqueline Da Rocha e Silva,Michael Näbauer,Marcel Weber,Gilbert H.L. Tang,Megan Heitkemper,Shih-Wa Ying,Jean-Noel Trochu,Saibal Kar,Rebecca T. Hahn,Georg Nickenig,Georg Nickenig,Ralph Stephan von Bardeleben,Martin Geyer,Peter Wenaweser,Patric Biaggi,Ioannis Kapos,Said Alsidawi,Philipp Lurz,Dabit Arzamendi,Regueiro Ander,Manuel Sabate,Anuradha Lala-Trindade,David Adams,Julie Swain,Mathias Orban,Jörg Hausleiter,Ottavio Alfieri,Eustachio Agricola,Matteo Montorfano,Jan-Malte Sinning,Alexander Tamm,Steffen Hoffmann,Marek Kowalski,Andrea Garatti,Alessandra Pecoraro,Gessica Motta,Maurizio Tusa,Michel Zuber,Stephan Windecker,Michael Samara,Karol Mudy,Sachin Parikh,Dee Dee Wang,Nicolas Piriou,Karl-Philipp Rommel,Christian Binner,Gustavo Jimenez,Xavier Freixa,Antonio Serra,David Lim,Stamatios Lerakis,Nicola Buzzatti,Marta Baragagna,Claudia Tiburtius,Carmelo Grasso,Federico De Marco,Francesco Maisano,Maurizio Taramasso,Richard Bae,Tiberio Frisoli,Patrice Guerin,Philipp Hartung,Sumeet Mitter,Noah Moss,Thomas Stocker,Francesco Ancona,Eustachio Agricola,Cristina Capogrosso
DOI: https://doi.org/10.1161/CIRCINTERVENTIONS.122.012888
2023-08-17
Abstract:Circulation: Cardiovascular Interventions, Volume 16, Issue 8, Page e012888, August 1, 2023. BACKGROUND:Tricuspid regurgitation (TR) is a common and progressive valve disease with significant mortality and hospitalization burden. Tricuspid transcatheter edge-to-edge repair provides a treatment option for high-risk patients with primary and secondary TR.METHODS:The TRILUMINATE trial ([Trial to Evaluate Treatment With Abbott Transcatheter Clip Repair System in Patients With Moderate or Greater Tricuspid Regurgitation]; n=85) is an international, prospective, single-arm, multicenter study to investigate the safety and performance of tricuspid transcatheter edge-to-edge repair with the TriClip implant in patients with symptomatic moderate or greater TR. Echocardiographic assessment was performed at a core laboratory. Outcomes included safety and clinical effectiveness and echocardiographic assessment of TR.RESULTS:At 2 years, TR was reduced to moderate or less in 60% of subjects, and reduction of at least 1 grade was achieved in 85.4% of subjects. TR reduction was sustained in 75% of the patients. While most metrics suggest the majority of favorable remodeling occurred within the first 30 days post-procedure, both right ventricular end diastolic diameter and tricuspid annular plane systolic excursion show signals of continued favorable remodeling through 2 years. Substantial improvements in 6-minute walking distance, New York Heart Association functional class, and Kansas City Cardiomyopathy Questionnaire score were sustained from 30 days to 2 years. Even with low rates of cardiovascular mortality (15.3%) and all-cause mortality (18.7%) noted at 2 years, all-cause hospitalization rate decreased from 1.30 events per patient-year 1 year before device implantation to 0.66 events per patient-year 2 years after the TriClip procedure, representing a reduction of 49% (P<0.0001).CONCLUSIONS:Tricuspid transcatheter edge-to-edge repair using the TriClip implant was found to be safe and effective, with sustained benefits at 2 years in subjects with symptomatic moderate or greater TR. Repair efficacy was durable at 2 years in 75% of the patients.REGISTRATION:URL:https://www.clinicaltrials.gov; Unique identifier: NCT03227757.
cardiac & cardiovascular systems